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Long acting 2 agonists and the risk of life threatening asthma
Pierre Ernst
Salmeterol was introduced on the market in the UK in 1990 been confirmed to occur in a general practice setting in the UK. 6 Such channelling of prescriptions has also been and subsequently elsewhere amid controversy surrounding the safety of short acting 2 agents. This controversy led clearly shown to have occurred for the short acting 2 agent fenoterol and remains the most likely explanation for the to caution on the part of physicians, except maybe in the USA, and a wide adoption of long acting 2 agonists was, link between this medication and life threatening asthma described in New Zealand and in Saskatchewan. 7 8 Simat the least, delayed; impressions left by the controversy probably still limit the sale of this agent. US physicians ilarly, the relationship between excessive and increasing use of short acting 2 agents as a class and the occurrence became wary following the report of deaths among patients who misused salmeterol for acute relief after the drug was of life threatening asthma is best explained by the increasing need for immediate relief among patients experiencing marketed as first line therapy for asthma.
1
Concern regarding long acting 2 agonists relates to a progressive loss of control of their disease. 9 10 The attempt by Williams and colleagues to dissociate such confounding possible increase in the risk of life threatening attacks and, potentially related to such an increase, the possibility that by severity as an explanation for the link between salmeterol and life threatening asthma from that suggested as the 2 agonists in general may cause an increase in the severity of asthma over time when used regularly. A post-marketing probable explanation for the link between fenoterol and life threatening asthma is not convincing. or phase IV clinical trial of salmeterol compared with salbutamol four times daily did little to allay concerns A second concern is that regular or sustained use of 2 agonists may cause worsening of asthma severity over time regarding an increase in the risk of life threatening asthma by providing a best estimate of a threefold increase in the as first suggested by Sears et al. 11 Certainly there is now ample evidence that sustained use of 2 agents is associated risk of death in the salmeterol group 2 ; while not statistically significant, this effect is, if accurate, clinically important.
with loss of bronchoprotection to non-specific bronchoconstrictors such as methacholine and adenosine and, of Thankfully, near fatal and fatal attacks of asthma remain rare events and are therefore not amenable to study in potentially greater clinical importance, may result in a greater inflammatory response of the airways to allergens.
12
randomised clinical trials nor with all but the largest cohort studies. The most efficient design for the study of such rare Such tolerance is not avoided by the concomitant use of inhaled corticosteroids. 13 By contrast, there is good evievents is the case-control study. Williams and colleagues in the current issue of Thorax 3 report on a case-control study dence that use of long acting 2 agonists for periods of at least six months results in excellent and continued control of the relationship between asthma therapy, principally salmeterol, and near fatal asthma. They found that subjects of asthma symptoms and that the beneficial effect on lung function is maintained. 14 Furthermore, several studies have admitted to an intensive care unit (ICU) during an acute attack of asthma were more than twice as likely (odds ratio now shown that, among patients whose asthma is undertreated, both formoterol and salmeterol provide long term 2.32) to have been prescribed salmeterol than patients admitted to hospital, but not to the ICU. Use of medcontrol of symptoms and lung function (FEV 1 or PEF) across a wide range of doses of inhaled corticosteroids ications prior to the acute attack was determined by close examination of clinical information available at preand the benefit obtained is approximately equivalent to doubling the dose of inhaled corticosteroids. 15-17 Salmeterol sentation of the patients (both cases and controls) to one of 14 district hospitals. After restricting the comparison to also allows a reduction in the daily dose of inhaled corticosteroids in patients with stable asthma. 18 Preliminary evithe more severe group of patients who had been admitted to hospital in the previous 12 months, the association was dence suggests, however, that this may be at the cost of an increase in inflammation of the airways. 12 19 The polessened (odds ratio 1.42) and was no longer statistically significant. The authors conclude that a true causal link tential long term implications of such inflammation and the airway remodelling which may result is unknown. between salmeterol use and life threatening asthma is unlikely and that any apparent association is probably due Of potential concern when prescribing a long acting 2 agonist is a decrease in response to short acting agents if to confounding by indication -that is, patients with severe asthma are more likely both to have a near fatal attack and asthma worsens acutely. While decreased sensitivity to salbutamol with the use of salmeterol can be demonto be prescribed salmeterol by their physician.
In support of this interpretation of their findings, the strated, 20 at least in stable patients, no lessening in the combined degree of brochodilatation nor a decrease in the authors provide evidence to suggest that, in the population they studied, salmeterol was preferentially prescribed to response to a short acting agent is seen after stopping salmeterol. than even a worse case scenario for the purported adverse weaker bronchodilator potency and its association with BMJ 1997; 314:1441-6. 19 Cockcroft DW, Swystun VA, Bhagat R, Kalra S. Salmeterol and airway substantial morbidity. 25 The two currently available long response to allergen. Can Respir J 1997; 4:37-40. acting 2 agonists, salmeterol and formoterol, appear com- 
